Abbvie Inc
NYSE:ABBV 4:00:00 PM EDT
Products, Regulatory
Abbvie's Rinvoq Meets Primary And All Ranked Secondary Endpoints In Ulcerative Colitis study
Published: 12/09/2020 13:55 GMT
Abbvie Inc (ABBV) - Upadacitinib (rinvoq™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis.
Abbvie - Significantly More Upadacitinib-treated Patients Achieved Clinical Remission at Week 8 Versus Placebo.
Abbvie Inc - Safety Results in Study Were Consistent With Known Profile of Upadacitinib, With No New Safety Risks Observed.
Abbvie - Significantly More Upadacitinib-treated Patients Achieved Clinical Remission at Week 8 Versus Placebo.
Abbvie Inc - Safety Results in Study Were Consistent With Known Profile of Upadacitinib, With No New Safety Risks Observed.